Akt activation upregulates SREBP1 gene expression, and it also inhibits the ubiquitin-proteasome pathway degradation of SREBP1 through protein arginine methyltransferase 5 (PRMT5), inducing SREBP1 hyperactivity, which results in de novo lipogenesis and tumor growth [167]. Here, SREBF1 is linked to neoplasm.